Peripherin and periaxin, biomarkers of peripheral nerve axonal damage and acute demyelination, respectively, have recently been validated in the inflammatory neuropathies Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This evidence concerns the gene PRPH and chronic inflammatory demyelinating polyradiculoneuropathy.